MediWound Ltd. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
259.00
601.00
1,558.00
2,496.00
3,401
Cost of Goods Sold (COGS) incl. D&A
335.00
2,834.00
2,605.00
2,270.00
1,688.00
2,191
Gross Income
335.00
2,575.00
2,004.00
712.00
808.00
1,210
SG&A Expense
7,246.00
18,852.00
19,223.00
19,443.00
14,495.00
11,956
EBIT
7,581.00
21,427.00
21,227.00
20,155.00
13,687.00
10,746
Unusual Expense
808.00
3,879.00
764.00
1,621.00
-
6,779
Non Operating Income/Expense
60.00
1,444.00
1,496.00
765.00
1,195.00
2,110
Interest Expense
1,669.00
57.00
-
-
-
-
Pretax Income
8,501.00
18,875.00
21,671.00
18,885.00
14,533.00
5,665
Consolidated Net Income
8,501.00
18,875.00
21,671.00
18,885.00
14,533.00
5,665
Net Income
8,501.00
18,875.00
21,671.00
18,885.00
14,533.00
5,665
Net Income After Extraordinaries
1,651.00
18,875.00
21,254.00
18,885.00
6,917.00
10,273
Net Income Available to Common
15,351.00
18,875.00
22,088.00
18,885.00
22,149.00
1,057
EPS (Basic)
3.72
0.95
1.02
0.86
0.95
0.04
Basic Shares Outstanding
21,297.80
19,940.00
21,718.00
21,862.20
23,341.00
27,113.60
EPS (Diluted)
0.72
0.95
1.02
0.86
0.95
0.04
Diluted Shares Outstanding
21,297.80
19,940.00
21,718.00
21,862.20
23,341.00
27,113.60
EBITDA
7,246.00
20,935.00
20,724.00
19,566.00
13,120.00
10,169
Non-Operating Interest Income
1.00
174.00
288.00
414.00
349.00
412

About MediWound

View Profile
Address
42 Hayarkon Street
Yavne HM 8122745
Israel
Employees -
Website http://www.mediwound.com
Updated 07/08/2019
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialize novel products to address unmet needs in the fields of severe burn; chronic and other hard-to-heal wounds; and connective tissue disorders. Its medicinal product, NexoBrid, is used to remove eschar in adults patients with deep partial- and full-thickness thermal burns. The company was founded by Lior Rosenberg and Marian Gorecki on January 27, 2000 and is headquartered in Yavne, Israel.